血必净治疗大肠癌术后病人全身炎症反应临床分析

Clinical Analysis of Xuebijing in Treating Postoporative Colorectal Carcinoma Patient with Systemic Inflammatory Response

目的:评价血必净辅助治疗大肠癌术后病人全身炎症反应综合症(SIRS)的临床疗效。方法:收集本院ICU病房内诊断为SIRS的大肠癌切除术后患者39例,随机分为治疗组22和对照组17例。对照组给予常规抗炎治疗;治疗组在此基础上加用血必净注射液100mL,bid,疗程7天。测定肿瘤坏死因子(TNF-α)、白细胞介素(IL-6)、生理和慢性健康状况评分Ⅱ(APACHEⅡ)、白细胞及中性粒细胞百分比与对照组比较。结果:治疗组第7天TNF-α、IL-6、APACHEⅡ、白细胞及中性粒细胞百分比与对照组比较,有统计学差异(P<0.05);治疗组脓毒症发生率较对照组显著下降,且具有统计学差异(P<0.05);治疗组患者最终死亡率较对照组显著下降,两组间患者死亡率差别有统计学意义(P<0.05)。结论:大肠癌切除术后病人发生全身炎症反应时在常规抗炎等支持治疗的基础上加用血必净注射液,能降低脓毒血症发生率,最终降低其死亡率。

Objective ： To evaluate the clinical effect of the Xuebijing in treating postoperative colorectai carcinoma eases with Systemic Inflammatory Response. Methods： 39 postoperative colorectaI carcinoma cases were randomly divided into two groups. 22 cases in xuebijing group and 17 eases in contrast group,the contrast group was routine treatment,the control group gave routine treatment and xuebijing injection 100mL iv drip bid for 7d. Then the plasma endotoxin, tumor necrosis factor - α （ TNF - α） ,interleukin - 6 （ IL - 6） levels, the WBC, the percent of neutrephil and APACHEⅡ were measured and compared. Results ： The plasma endotoxin TNF -α, IL - 6 levels and the incidence rate of sepsis and the death rate in xuebijing group trended to decrease and significantly lower than that in contrast group （ P 〈 0. 05 ）. Conlusion： Xuebijing can effectively treat Critical Patient of colorectai carcinoma. It can obviously short the course of disease,improve the symptom, reduce the death rate. Xuebijing was improved effective for the prognosis.